These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2496903)

  • 21. [Whole-body retention of 99mTc-methylene diphosphonate in skeletal diseases].
    Zorn-Bopp E; Büll U; Münzing W; Lang P; Moser EA
    Nuklearmedizin; 1983 Feb; 22(1):24-30. PubMed ID: 6223277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of various rhenium-188-labeled diphosphonates for the treatment of bone metastases.
    Hsieh BT; Hsieh JF; Tsai SC; Lin WY; Wang SJ; Ting G
    Nucl Med Biol; 1999 Nov; 26(8):973-6. PubMed ID: 10708313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Technetium-99m MDP vs technetium-99m dicarboxypropane diphosphonate. A clinical comparison in various pathologic conditions.
    Godart G; Durez M; Bevilacqua M; Abramovici J; Robience Y
    Clin Nucl Med; 1986 Feb; 11(2):92-7. PubMed ID: 3769350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative measurements of bone remodeling using 99mTc-methylene diphosphonate bone scans and blood sampling.
    Moore AE; Blake GM; Fogelman I
    J Nucl Med; 2008 Mar; 49(3):375-82. PubMed ID: 18287266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diphosphonates in the evaluation of metabolic bone disease.
    Fogelman I; Smith ML
    Clin Rheumatol; 1982 Mar; 1(1):41-4. PubMed ID: 6236012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of synthetic steroid (Org OD 14): effect on skeletal metabolism by 24-h whole-body retention of diphosphonate.
    Fogelman I; Bessent RG; Smith ML; Hart DM; Lindsay R
    Maturitas; 1981 Dec; 3(3-4):265-9. PubMed ID: 6801438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biokinetics of bone tracers by means of deconvolution analysis--comparison of 99mTc MDP, 99mTc DPD and 99mTc EHDP.
    Knop J; Stritzke P; Kröger E; Schneider C; Wasmus G
    Nuklearmedizin; 1982 Aug; 21(4):145-9. PubMed ID: 6216459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age-related alterations in skeletal metabolism--24-hr whole-body retention of diphosphonate in 250 normal subjects: concise communication.
    Fogelman I; Bessent R
    J Nucl Med; 1982 Apr; 23(4):296-300. PubMed ID: 6802938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 99mTc-diphosphonate whole-body retention measurements using a conic-beam collimator and a scintillation detector.
    Vattimo A
    J Nucl Med Allied Sci; 1987; 31(3):291-4. PubMed ID: 3121810
    [No Abstract]   [Full Text] [Related]  

  • 30. Global skeletal uptake of 99mTc-methylene diphosphonate (GSU) in patients affected by endocrine diseases: comparison with biochemical markers of bone turnover.
    Scillitani A; Dicembrino F; Chiodini I; Minisola S; Fusilli S; Di Giorgio A; Garrubba M; D'Aloiso L; Frusciante V; Torlontano M; Modoni S; Trischitta V; Trischitta V; Carnevale V
    Osteoporos Int; 2002 Oct; 13(10):829-34. PubMed ID: 12378373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of a blood-sampling method for the measurement of 99mTc-methylene diphosphonate skeletal plasma clearance.
    Moore AE; Blake GM; Fogelman I
    J Nucl Med; 2006 Apr; 47(4):581-6. PubMed ID: 16595490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
    Brenner W; Kampen WU; Kampen AM; Henze E
    J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of lesion to normal bone uptake ratios of skeletal radiopharmaceuticals by QARG (quantitative autoradiography).
    Ghiron J; Volkert WA; Garlich J; Holmes RA
    Int J Rad Appl Instrum B; 1991; 18(2):235-40. PubMed ID: 2026500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of bone imaging with Tc-99m DPD and Tc-99m MDP: concise communication.
    Buell U; Kleinhans E; Zorn-Bopp E; Reuschel W; Muenzing W; Moser EA; Seiderer M
    J Nucl Med; 1982 Mar; 23(3):214-7. PubMed ID: 6460854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Computer analysis of Tc-99m DPD and Tc-99m MDP kinetics in humans: concise communication.
    Mele M; Conte E; Fratello A; Pasculli D; Pieralice M; D'Addabbo A
    J Nucl Med; 1983 Apr; 24(4):334-8. PubMed ID: 6834136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone-seeking properties of Tc-99m carbonyl diphosphonic acid, dihydroxy-methylene diphosphonic acid and monohydroxy-methylene phosphoinic acid: concise communication.
    Wang TS; Fawwaz RA; Johnson LJ; Mojdehi GE; Johnson PM
    J Nucl Med; 1980 Aug; 21(8):767-70. PubMed ID: 7400832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is (99m)Tc-labelled pamidronate a better agent than (99m)Tc-medronate for bone imaging?
    Kumar V; Kumar D; Howman-Giles RB; Little DG
    Nucl Med Commun; 2007 Feb; 28(2):101-7. PubMed ID: 17198350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease.
    Fogelman I; Bessent RG; Turner JG; Citrin DL; Boyle IT; Greig WR
    J Nucl Med; 1978 Mar; 19(3):270-5. PubMed ID: 564941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A report on the incidence of intestinal 99mTc-methylene diphosphonate uptake of bone scans and a review of the literature.
    Ergün EL; Kiratli PO; Günay EC; Erbaş B
    Nucl Med Commun; 2006 Nov; 27(11):877-85. PubMed ID: 17021428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diphosphonate bone scanning agents--current concepts.
    Fogelman I
    Eur J Nucl Med; 1982; 7(11):506-9. PubMed ID: 6217074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.